

Meeting Information

Meeting link:

<https://stateofalaska.webex.com/stateofalaska/j.php?MTID=m6a6824fa9beafe241eab43097f882caf>

Meeting number:

133 617 4709

Password:

AKMCDPTSFY2021

Agenda:

Public notice link to agenda: <http://notice.alaska.gov/199865>

1. Call to Order – Chair 8:00 am
2. Roll Call 8:05 am
3. Public Comment, including health care professionals
4. Class review, discussion & vote.
 - a. Cystic Fibrosis
 - b. Central Nervous System
5. Break as needed – 15 minutes
6. Review minutes from September 2020 meeting
7. Comments from Committee Members or Chair
8. Adjourn

Audio Connection is via phone at 800.315.6338 Code 24251#

To minimize background noise, please keep your phone muted if you are not talking.

This meeting is being recorded.

If you are a member of the public, a healthcare professional, or an industry representative and wish to provide public comment at the meeting today, please send the following information via the Chat function to the host:

1. Name and credentials (if applicable)
2. Who you are representing/affiliation(s) (company, self, organization, group)
3. The drug class for which you wish to provide public comment
4. Any conflict of interest disclosure (i.e., financial affiliations with the topic you are presenting on)

The Chair will call on pharmaceutical industry representatives during the appropriate class discussion. If you are an Alaskan healthcare professional (not affiliated with industry), the chair will provide an opportunity at the beginning of the meeting for comments.

Note that while the CMS Open Payments database is used to identify potential conflicts of interest, it is the speaker's responsibility to disclose any conflicts of interest prior to addressing the committee.

All industry presentations (limited to 3 min) must be consistent with Federal regulation; any misrepresentation of products discussed by pharmaceutical representatives will be reported to the FDA's Office of Prescription Drug Promotion.

<https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/opdp-regulatory-information>

Written comments for this meeting may be sent to Chuck Semling at Charles.Semling@alaska.gov.